晚期肾癌系统治疗现状与进展

doi:10.3969/j.issn.2095-378X.2023.04.001

摘要/Abstract

摘要： 肾癌是泌尿系统常见的恶性肿瘤,起病隐匿,进展迅速。晚期肾癌预后差,主要依靠系统治疗。现行系统治疗方案主要为靶向治疗和免疫治疗。而新型靶向药物、靶向免疫联合新方案、HIF-2α抑制剂、益生菌联合治疗等为晚期肾癌系统治疗提供了更多可能。本文总结了近年来晚期肾癌系统治疗的现状及进展,以期为临床治疗提供借鉴。

关键词: 肾细胞癌, 系统性治疗, 靶向治疗, 免疫治疗

Abstract: Renal cell carcinoma is a common type of urinary cancer with insidious onset and rapid progression. Advanced renal cell carcinoma has poor prognosis and primarily depends on systemic therapy which mainly composed of targeted therapy and immunotherapy. Recently, new targeted drugs, immuno-targeted combination therapy, HIF-2α inhibitors, and probiotic combination therapy provide more possible options for the treatment. In this review, we gave an overview of the advances in systemic therapy of advanced renal cell carcinoma, aiming to help make clinical decisions.

Key words: Renal cell carcinoma, Systemic therapy, Targeted therapy, Immunotherapy

中图分类号:

R735.3

胡青岳, 翟炜, 郑军华. 晚期肾癌系统治疗现状与进展[J]. 外科研究与新技术, 2023, 12(4): 237-242.

HU Qingyue, ZHAI Wei, ZHENG Junhua. Advances in systemic therapy of advanced renal cell carcinoma[J]. Surgical Research and New Technique, 2023, 12(4): 237-242.

参考文献

[1] Motzer RJ, Jonasch E, Agarwal N, et al.Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(1): 71-90.
[2] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] Bukowski RM.Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2[J]. Cancer, 1997, 80(7): 1198-1220.
[4] National Comprehensive Cancer Network. Kidney cancer (v.1.2024)[EB/OL].(2023-05-12)[2023-11-10].https://www.nccnchina.org.cn/guide/detail/406.
[5] Hsieh JJ, Purdue MP, Signoretti S, et al.Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3(1): 17009.
[6] Amato RJ.Chemotherapy for renal cell carcinoma[J]. Semin Oncol, 2000, 27(2): 177-186.
[7] Gupta K, Miller JD, Li JZ, et al.Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review[J]. Cancer Treat Rev, 2008, 34(3): 193-205.
[8] Motzer RJ, Bacik J, Schwartz LH, et al.Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2004, 22(3): 454-463.
[9] Patard JJ, Rioux-Leclercq N, Fergelot P.Understanding the importance of smart drugs in renal cell carcinoma[J]. Eur Urol, 2006, 49(4): 633-643.
[10] Pattel PH, Chadalavada RS, Chaganti RS, et al.Targeting von Hippel-Lindau pathway in renal cell carcinoma[J]. Clin Cancer Res, 2006, 12(24): 7215-7220.
[11] Choueiri TK, Escudier B, Powles T, et al.Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2016, 17(7): 917-927.
[12] Larkin JM, Eisen T.Kinase inhibitors in the treatment of renal cell carcinoma[J]. Crit Rev Oncol Hematol, 2006, 60(3): 216-226.
[13] Motzer RJ, Escudier B, Oudard S, et al.Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase Ⅲ trial[J]. Lancet, 2008, 372(9637): 449-456.
[14] Motzer RJ, Hutson TE, Tomczak P, et al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2009, 27(22): 3584-3590.
[15] Rini BI, Escudier B, Tomczak P, et al.Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial[J]. Lancet, 2011, 378(9807): 1931-1939.
[16] Sternberg CN, Davis ID, Mardiak J, et al.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2010, 28(6): 1061-1068.
[17] Motzer RJ, Hutson TE, Glen H, et al.Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial[J]. Lancet Oncol, 2015, 16(15): 1473-1482.
[18] Molina AM, Hutson TE, Nosov D, et al.Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study[J]. Eur J Cancer, 2018, 94(1): 87-94.
[19] Motzer RJ, Nosov D, Eisen T, et al.Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase Ⅲ trial[J]. J Clin Oncol, 2013, 31(30): 3791-3799.
[20] Sheng X, Ye D, Zhou A, et al.Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase Ⅲstudy (CONCEPT)[J]. Eur J Cancer, 2023, 178(1): 205-215.
[21] Gore ME, Szczylik C, Porta C, et al.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial[J]. Lancet Oncol, 2009, 10(8): 757-763.
[22] Hudes G, Carducci M, Tomczak P, et al.Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med, 2007, 356(22): 2271-2281.
[23] Koh Y, Lim HY, Ahn JH, et al.Phase Ⅱ trial of everolimus for the treatment of nonclear-cell renal cell carcinoma[J]. Ann Oncol, 2013, 24(4): 1026-1031.
[24] Sánchez P, Calvo E, Durán I.Non-clear cell advanced kidney cancer: is there a gold standard?[J]. Anticancer Drugs, 2011, 22(Suppl 1): S9-S14.
[25] Pal SK, Tangen C, Thompson IM Jr., et al.A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet, 2021, 397(10275): 695-703.
[26] Choueiri TK, Heng DYC, Lee JL, et al.Efficacy of savolitinib vs sunitinib in patients with met-driven papillary renal cell carcinoma: the SAVOIR Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(8): 1247-1255.
[27] Motzer RJ, Escudier B, George S, et al.Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial[J]. Cancer, 2020, 126(18): 4156-4167.
[28] Motzer RJ, Escudier B, Mcdermott DF, et al.Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813.
[29] Mcdermott DF, Lee, JL, Bjarnason GA, et al. Open-label, single-arm phase Ⅱ study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma[J]. J Clin Oncol, 2021, 39(9): 1020-1028.
[30] Motzer RJ, Tannir NM, Mcdermott DF, et al.Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290.
[31] Motzer RJ, Tannir NM, Mcdermott DF, et al.661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)[J]. Ann Oncol, 2021, 32(5): S685-S687.
[32] Vasudev NS, Ainsworth G, Brown S, et al. Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: A randomized phase Ⅱ trial (PRISM) [J]. J Clin Oncol, 2023, 10,(23):00236
[33] Rini BI, Plimack ER, Stus V, et al.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127.
[34] Rini BI, Plimack ER, Stus V, et al.Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426[J]. J Clin Oncol, 2021, 39(15): 4500.
[35] Rini BI, Plimack ER, Stus V, et al.Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426[J]. J Clin Oncol, 2023, 41(17): 4501.
[36] Choueiri TK, Powles T, Burotto M, et al.Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2021, 384(9): 829-841.
[37] Burotto M, Powles T, Escudier B, et al.Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial[J]. J Clin Oncol, 2023, 41(6): 603.
[38] Motzer R, Alekseev B, Rha SY, et al.Lenvatinib plus pembrolizumab or everolimus for advanced renal cell Carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300.
[39] Motzer RJ, Porta C, Eto M, et al.Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)[J]. Journal of Clinical Oncology, 2023, 41(16): 4502.
[40] Motzer RJ, Penkov K, Haanen J, et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115.
[41] Choueiri TK, Motzer RJ, Rini BI, et al.Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma[J]. Ann Oncol, 2020, 31(8): 1030-1039.
[42] Choueiri TK, Powles T, Albiges L, et al.Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma[J]. N Engl J Med, 2023, 388(19): 1767-1778.
[43] Powles T, Motzer RJ, Albiges L, et al.Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk[J]. J Clin Oncol, 2023, 41(6): 605.
[44] Sheng XN, Ye MJ, Zou Q, et al.RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase Ⅲ study[J]. Annals of Oncology, 2023, 34(2): 1013-1031.
[45] Albiges L, Barthélémy P, Gross-Goupil M, et al.TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma[J]. Ann Oncol, 2021, 32(1): 97-102.
[46] Choueiri TK, Albiges L, Hammers H, et al.TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor[J]. J Clin Oncol, 2022, 40(6): 405.
[47] Mcdermott DF, Lee JL, Ziobro M, et al.Open-label, single-arm, phase Ⅱ study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma[J]. J Clin Oncol, 2021, 39(9): 1029-1039.
[48] Albiges L, Gurney H, Atduev V, et al.Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial[J]. Lancet Oncol, 2023, 24(8): 881-891.
[49] Lee CH, Voss MH, Carlo MI, et al.Phase Ⅱ trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates[J]. J Clin Oncol, 2022, 40(21): 2333-2341.
[50] Suárez C, Larkin JMG, Patel P, et al.Phase Ⅱ study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)[J]. J Clin Oncol, 2023, 41(14): 2493-2502.
[51] Jonasch E, Donskov F, Iliopoulos O, et al.Belzutifan for renal cell carcinoma in von Hippel-Lindau disease[J]. N Engl J Med, 2021, 385(22): 2036-2046.
[52] Choueiri TK, Mcdermott DF, Merchan J, et al.Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2023, 24(5): 553-562.
[53] Gebrael G, Sahu KK, Agarwal N, et al.Update on combined immunotherapy for the treatment of advanced renal cell carcinoma[J]. Hum Vaccin Immunother, 2023, 19(1): 2193528.
[54] Motzer RJ, Schmidinger M, Eto M, et al.LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy[J]. Future Oncol, 2023, 19(2): 113-121.
[55] Dizman N, Meza L, Bergerot P, et al.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial[J]. Nat Med, 2022, 28(4): 704-712.
[56] Ebrahimi H, Meza LA, Lee K, et al.Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial[J]. J Clin Oncol, 2023, 41(17): 104.